Difference between revisions of "Doxorubicin (Adriamycin)"
m |
Andrewc072 (talk | contribs) |
||
| Line 20: | Line 20: | ||
*[[Non-Hodgkin lymphoma]] | *[[Non-Hodgkin lymphoma]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
| + | *[[Sarcoma]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Uterine cancer]] | *[[Uterine cancer]] | ||
Revision as of 16:04, 28 March 2013
Also known as Adriamycin PFS, Adriamycin RDF, hydroxydaunorubicin, or Rubex.
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Bone cancer
- Breast cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Hepatobiliary cancer
- Hodgkin lymphoma
- Multiple myeloma
- Non-Hodgkin lymphoma
- Renal cancer
- Sarcoma
- Thymoma
- Uterine cancer
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
References
- Drug index
- Chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Vesicant chemotherapy
- Acute lymphocytic leukemia medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Multiple myeloma medications
- Non-Hodgkin lymphoma medications
- Renal cancer medications
- Thymoma medications
- Uterine cancer medications